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Hajdu-Cheney syndrome is a rare, autosomal dominant skeletal dysplasia marked 
by acro-osteolysis of the distal phalanges and severe osteoporosis. Although there 
are more than 60 reports published to date, proper treatment and subsequent out-
come have been scarce. Herein, we report a progress of anti-resorptive therapy 
with zoledronic acid, in a woman with Hajdu-Cheney syndrome. Results suggest 
that anti-resorptive therapy may be important in delaying the progress of osteopo-
rosis and preventing fractures, but not necessarily acro-osteolysis itself. 
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INTRODUCTION
Hajdu-Cheney syndrome (HCS) is a rare disorder, characterized by prominent 
skeletal dysplasia which includes craniofacial change, dental anomalies, short stat-
ure, and acro-osteolysis and generalized osteoporosis.1-3 Although the etiology and 
pathogenesis are unknown, inadequate bone mass acquisition, subsequent bone 
loss may contribute to advanced osteoporosis in this syndrome.4-6 The aim of the 
treatment for the osteoporosis in HCS is to prevent the frequent occurrence of fra-
gility fracture. Herein, we report the progress of anti-resorptive therapy with zole-
dronic acid in a woman with HCS.
CASE REPORT
A 41-year-old, premenopausal woman was referred for evaluation of short stature 
and low bone mass. She went through surgical correction of the patent ductus arte-
riosus at the age of 28. She underwent complete dental extraction for poor root de-
velopment. She had persistent pain on both hands and feet and gait disturbance for 
nearly 30 years. Her menstruation was normal, and there was no consanguinity in 
her family members, including her parents, two younger brothers, two older and 
one younger sister. The patient’s 7-year-old daughter was phenotypically normal Sena Hwang, et al.
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bance and osteoporosis treatment. At first, she began on 
daily calcium carbonate 1,500 mg/day and cholecalciferol 4 
mg/day. Then, once-yearly 5 mg intravenous zoledronic 
acid (diluted in 100 mL isotonic saline and infused over no 
less than 15 minutes) was started. The rheumatologist used 
empirical prednisolone 5 mg/day for her persistent arthral-
gia. However, they discontinued glucocorticoids 6 months 
later, because there was no definite evidence of rheumatoid 
arthritis. After administration of the second dose of zole-
dronic acid, BMD at L-spine decreased by 5.3 % to 0.642 
g/cm2 (T score -3.2) without any changes in femoral BMD. 
Follow-up radiographs of the hand and feet showed pro-
gressive acro-osteolysis (Fig. 2C and D). C-telopeptide was 
suppressed by 45.8%, 0.107 to 0.058 ng/mL (≤0.573) dur-
ing the first 2 years but increased to 0.167 ng/mL over the 
recent 1 year, and osteocalcin was gradually decreased by 
60.4% from 15.42 to 6.10 ng/mL (0.7-24.7) during the fol-
low-up period (Fig. 3). We administered the third dose of 
zoledronic acid in March 2010, and she remained free of 
fracture this time. The pain in both hands and feet was also 
much relieved from visual analysis score 10 to 5.
DISCUSSION
Since our patient was first diagnosed as HCS in Korea 3 
years ago, another HCS case was recently reported in Korea.8 
but had not been confirmed with radiologic examination. 
Physical examination revealed short stature (height, 139 
cm; weight, 52 kg), coarse facial features with microgna-
thia, and short digits showed pseudo-clubbing (Fig. 1A and 
B) but otherwise unremarkable. The following hematologi-
cal and biochemical results were normal: complete blood 
count, electrolytes, liver function, renal function, serum cal-
cium, phosphate, alkaline phosphatase, thyroid stimulating 
hormone (TSH), estradiol, parathyroid hormone (PTH), 
and urine analysis. Initial 25-hydroxy-vitamin D was 27.12 
ng/mL (≥30). Skeletal survey revealed loss of the terminal 
phalanges of all fingers bilaterally and osteolytic defect at 
the first metatarsal head of both feet (Fig. 2A and B). Later-
al skull radiograph showed wormian bones with persistent 
patency of cranial sutures, bathrocephaly, and midfacial hy-
poplasia. Bone mineral density (BMD) of the lumbar (L) 
spine and the mean total hip by dual-energy X-ray absorpti-
ometry were 0.678 and 0.958 g/cm2, respectively, corre-
sponding to T scores of -3.0 and 0.9. Iliac crest bone biopsy 
showed low bone volume and thin and widely separated tra-
beculae compared to the data of normal Korean women7 
(Fig. 1C), with normal incorporation of tetracycline label 
(Fig. 1D). Her chromosome analysis and mental develop-
ment were normal.
A diagnosis of a sporadic form of HCS was made based 
on the characteristic clinical, radiographic, and densitomet-
ric phenotypes. She started rehabilitation for gait distur-
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Fig. 1. Clinical photographs of the face (A) and hands and feet (B). Micrognathia is evident. Distal clubbing of the fingers and toes are not-
ed. Iliac bone biopsy shows decreased bone volume and thin and widely separated trabeculae (C) with normal incorporation of tetracy-
cline label (D).Hajdu-Cheney Syndrome with Zoledronic Acid Therapy
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strating the treatment outcome of acro-osteolysis and osteo-
porosis in HCS, one with bisphosphonate and the other 
with bisphosphonate combined with teriparatide.15-17 The L-
spine BMD of the patient with alendronate had increased 
by 18.3% over 4 years, and that of the other patient with 
pamidronate and teriparatide increased by 24% in 9 months. 
They did not sustain any further fractures during treatment 
period. On the contrary, there was no effect on acro-osteol-
ysis. In other acro-osteolysis syndrome, nodulosis, atorh-
topathy and osteolysis syndrome, pamidronate therapy suc-
cessfully decreased joint pain, improved functional ability, 
and significantly increased BMD.18
In our case, relatively low bone turnover in the begin-
ning, reduced physical activity and use of glucocorticoid in 
between, might have attributed to less response in BMD. 
Brennan, et al. proposed diagnostic criteria based on the clini-
cal and radiological characteristics at different stages of life.9-11 
Our patient had all typical features of this syndrome. 
Acro-osteolysis is a hallmark of the syndrome. Nunziata, 
et al.4 suggested that acro-osteolysis may be sustained by lo-
cal acting factors stimulating osteoclastic resorption. Udell 
speculated a local increase in mast cells and elaboration of 
osteolytic cytokines could result in focal loss.6,12 Also, gener-
alized osteoporosis commonly coexisted in HCS, which is 
frequently associated with atraumatic vertebral and nonverte-
vral fractures.6,12 The etiology, pathogenesis or the causative 
gene of this syndrome is still unknown, but a number of re-
ports have suggested that low peak bone mass and high bone 
turnover may account for osteoporosis in HCS.12-14
Based on this speculation, there were two reports demon-
Fig. 2. Initial and posttreatment radiographs of the lumbar spine and both hands and feet. Diffuse osteoporosis through the lumbar spine 
is noted (A). There is complete loss or scale-like residue of the distal phalanges in all fingers, and clubbing of the terminal tufts is seen 
(B). Subluxation of the metatarsophlangeal joint of the left second toe, osteolytic thinning of the left fifth metatarsal, and shortening of the 
proximal phalanges are seen (B). Follow-up radiographs 2 months after administration of the third dose of zoledronic acid shows nor os-
teoporosis or vertebral fracture, and dense end-plates represent the biphosphonate effect (C). Note progressive worsening of osteolysis 
affecting the middle phalanges of the fingers as well as the phalanges of the feet and peri-articular bone loss (arrowheads)(D).
Fig. 3. Changes in bone turnover and bone mineral density (BMD) in response to zoledronic acid. L-spine BMD decreased by 5.3% from 
0.678 to 0.642 g/cm
2 over 3 years; C-telopeptide was suppressed by 45.8% from 0.107 to 0.058 ng/mL over the first 2 years but increased to 
0.167 ng/mL over the recent 1 year; and osteocalcin gradually decreased by 60.4% from 15.42 to 6.10 ng/mL during the follow-up period af-
ter 3 years of treatment. 
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long-term follow-up. J Bone Miner Res 1999;14:2036-41.
6. Udell J, Schumacher HR Jr, Kaplan F, Fallon MD. Idiopathic fa-
milial acroosteolysis: histomorphometric study of bone and litera-
ture review of the Hajdu-Cheney syndrome. Arthritis Rheum 
1986;29:1032-8.
7. Won YY, Chung YS, Park YK, Yoo VY. Correlations between mi-
crocomputed tomography and bone histomorphometry in Korean 
young females. Yonsei Med J 2003;44:811-5.
8. Han EJ, Mun JI, An SY, Jung YJ, Kim OH, Chung YS. A Case 
Report of Hajdu-Cheney Syndrome. Endocrinol Metab 2010;25: 
152-6.
9. Kawamura J, Matsubayashi K, Ogawa M. Hadju-Cheney syn-
drome. Report of a non-familial case. Neuroradiology 1981;21: 
295-301.
10. Brennan AM, Pauli RM. Hajdu--Cheney syndrome: evolution of 
phenotype and clinical problems. Am J Med Genet 2001;100:292-
310.
11. Marik I, Kuklik M, Zemkowa D, Kozlowski K. Hajdu-Cheney 
syndrome: report of a family and a short literature review. Austral-
as Radiol 2006;50:534-8.
12. Brown DM, Bradford DS, Gorlin RJ, Desnick RJ, Langer LO, 
Jowsey J, et al. The acro-osteolysis syndrome: Morphologic and 
biochemical studies. J Pediatr 1976;88:573-80.
13. Iwaya T, Taniguchi K, Watanabe J, Iinuma K, Hamazaki Y, Yoshi-
kawa S. Hajdu-Cheney syndrome. Arch Orthop Trauma Surg 
1979;95:293-302.
14. Lifchus-Ascher RJ, Tucci JR. Hajdu-Cheney syndrome in a 
19-year-old man. Endocr Pract 2006;12:690-4.
15. Drake WM, Hiorns MP, Kendler DL. Hadju-Cheney syndrome: 
response to therapy with bisphosphonates in two patients. J Bone 
Miner Res 2003;18:131-3.
16. McKiernan FE. Integrated anti-remodeling and anabolic therapy 
for the osteoporosis of Hajdu-Cheney syndrome. Osteoporos Int 
2007;18:245-9.
17. McKiernan FE. Integrated anti-remodeling and anabolic therapy 
for the osteoporosis of Hajdu-Cheney syndrome: 2-year follow-
up. Osteoporos Int 2008;19:379-80.
18. Al-Mayouf SM, Madi SM, Bin-Abbas BS. Cyclic intravenous 
pamidronate treatment in children with nodulosis, arthropathy and 
osteolysis syndrome. Ann Rheum Dis 2006;65:1672-3.
However, there was a worrisome result of progressive acro-
osteolysis in this patient, too. Aggravated osteolysis without 
subsequent bone formation due to strong inhibition from 
zoledronic acid might have contributed in worsening of the 
process. Therefore, we can speculate that the pathogenesis 
could be different between aco-osteolysis and osteoporosis, 
and bisphosphonate therapy may help to prevent at least the 
occurrence of fractures and suppress bone resorption in 
HCS, but not necessarily acro-osteolysis itself. This further 
suggests that the causative gene of HCS should be identi-
fied to properly determine the direction of treatment. 
Bisphosphonate therapy in our patient was well tolerated 
and somewhat effective in pain relief and prevention of 
bone fractures. However, in order to provide appropriate 
treatment and prevent further acro-osteolysis, pathogenesis 
of focal osteolysis and generalized osteoporosis must be elu-
cidated.
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